Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.64
$0.491.19%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -135.89M | -107.59M | -90.95M | -65.27M | -62.09M |
| Total Depreciation and Amortization | 877.00K | 628.00K | 478.00K | 388.00K | 325.00K |
| Total Amortization of Deferred Charges | 385.00K | 352.00K | 345.00K | 335.00K | 309.00K |
| Total Other Non-Cash Items | 16.83M | 14.38M | 13.01M | 12.82M | 13.38M |
| Change in Net Operating Assets | 306.00K | 3.20M | 1.84M | -3.99M | -951.00K |
| Cash from Operations | -117.49M | -89.03M | -75.28M | -55.71M | -49.03M |
| Capital Expenditure | -1.50M | -1.63M | -1.35M | -685.00K | -506.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 142.11M | 37.16M | -67.61M | -132.49M | -144.12M |
| Cash from Investing | 140.60M | 35.54M | -68.96M | -133.17M | -144.63M |
| Total Debt Issued | 10.00M | 10.00M | 5.00M | 5.00M | 20.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 120.18M | 100.68M | 787.00K | 75.09M | 75.07M |
| Repurchase of Common Stock | -- | -- | -136.00K | -136.00K | -136.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | -75.00K | -950.00K |
| Cash from Financing | 130.18M | 110.68M | 5.65M | 79.88M | 93.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 153.29M | 57.18M | -138.59M | -109.01M | -99.67M |